Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 342,116,416
  • Shares Outstanding, K 2,693,830
  • Annual Sales, $ 71,890 M
  • Annual Income, $ 16,540 M
  • 36-Month Beta 0.79
  • Price/Sales 4.76
  • Price/Cash Flow 15.34
  • Price/Book 4.89

Price Performance

See More
Period Period Low Period High Performance
1-Month
122.15 +4.18%
on 04/24/17
128.37 -0.86%
on 05/16/17
+5.50 (+4.52%)
since 04/21/17
3-Month
119.48 +6.51%
on 02/23/17
129.00 -1.35%
on 03/15/17
+7.74 (+6.48%)
since 02/22/17
52-Week
109.32 +16.41%
on 12/07/16
129.00 -1.35%
on 03/15/17
+14.62 (+12.98%)
since 05/20/16

Most Recent Stories

More News
Risperdal Lawsuits Continue to Plague Johnson & Johnson, With More Than 16,000 Filings Nationwide, Bernstein Liebhard LLP Reports

Johnson & Johnson and its Janssen Pharmaceuticals subsidiary continue to face legal claims over gynecomastia and other side effects allegedly associated with Risperdal. According to a May 8th filing with...

JNJ : 127.26 (+0.20%)
Hepatitis Therapeutics Market to Reach $25.8 Billion by 2025 - Key Players are Gilead, Merck, Johnson & Johnson, Bristol-Myers Squibb Company & AbbVie - Research and Markets

Research and Markets has announced the addition of the "Hepatitis Therapeutics Market Analysis By Disease Type (Hepatitis A, B, C) By Region (North America, Europe, Asia Pacific, Latin America,...

JNJ : 127.26 (+0.20%)
MRK : 64.04 (+0.41%)
BMY : 54.10 (+0.15%)
Cooler Heads, Smaller Losses

Cooler Heads, Smaller Losses

DE : 121.71 (+0.67%)
UVXY : 11.74 (-9.34%)
JNJ : 127.26 (+0.20%)
IOO : 85.27 (+0.28%)
CSX : 51.46 (+2.14%)
USCR : 69.85 (+2.34%)
VC : 100.07 (+0.11%)
ACCO : 11.25 (-1.75%)
TVIX : 25.60 (-9.12%)
AMC : 25.00 (-1.19%)
WDC : 87.98 (+1.52%)
PLCE : 111.00 (+4.91%)
NUE : 56.76 (+0.18%)
WMT : 78.55 (-0.28%)
Operation Smile's 35th Anniversary presented by Johnson & Johnson

Wednesday night, New York's top philanthropists, celebrities and supporters gathered in Chelsea for an evening honoring the work of famed photographer Brian Bowen Smith in commemoration of Operation Smile's...

JNJ : 127.26 (+0.20%)
Dow 30 Stock Roundup: Home Depot, Cisco, Wal-Mart Beat on Earnings

The Dow traversed another tenuous week, marked by key earnings results and political developments.

CSCO : 31.59 (+1.22%)
JPM : 84.70 (-0.09%)
JNJ : 127.26 (+0.20%)
XOM : 82.29 (+0.44%)
HD : 155.96 (-0.22%)
WMT : 78.55 (-0.28%)
Why Is Johnson & Johnson (JNJ) Up 4.4% Since the Last Earnings Report?

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

JNJ : 127.26 (+0.20%)
Pharma Stock Roundup: J&J's Pharma Pipeline Update, Shire's HAE Data & More

This week, industry bellwether J&J (JNJ) provided a look at its pharma pipeline while Shire was up on HAE data.

BAYRY : 131.2900 (+0.42%)
JNJ : 127.26 (+0.20%)
MRK : 64.04 (+0.41%)
LLY : 76.98 (-1.05%)
SHPG : 187.49 (-0.87%)
SNY : 49.16 (-0.30%)
BMY : 54.10 (+0.15%)
J&J (JNJ) Plans to Seek Approval for 10 New Drugs by 2021

Johnson & Johnson, Inc. (JNJ) discussed its future plans and showcased a strong pipeline of transformational medicines at a meeting held yesterday with industry analysts.

CATB : 1.36 (+0.74%)
VVUS : 1.08 (+3.85%)
JNJ : 127.26 (+0.20%)
PFE : 32.12 (-1.05%)
RM Global Partners Completes $30 Million First Closing of New Israel-Based Biopharma Fund

-- The RMGP Biopharma Fund will invest in the FutuRx portfolio, an Israel-based incubator founded by industry leaders Johnson & Johnson, Takeda Ventures, and OrbiMed

JNJ : 127.26 (+0.20%)
Shares of Colgate-Palmolive (CL) Pop as CEO May Want to Sell

On Wednesday, shares of leading global consumer products company Colgate-Palmolive Co. (CL) are popping, up over 5% to $75.25 per share in afternoon trading after the New York Post reported that its CEO,...

JNJ : 127.26 (+0.20%)
UL : 54.48 (+1.13%)
KHC : 91.18 (+1.00%)
PG : 86.21 (-0.03%)
CL : 74.28 (-0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Support & Resistance

2nd Resistance Point 128.20
1st Resistance Point 127.73
Last Price 127.26
1st Support Level 126.71
2nd Support Level 126.16

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.